The reliability of serum prostate specific antigen (PSA) measurements in men with acute urinary retention is unclear. Total PSA, free and complexed PSA were measured, and the free/total (f/t) PSA and complexed/total (c/t) PSA ratios calculated, prior to catheterisation and at 48 and 72 h post-catheterisation in 39 men with acute retention. Subsequent histology showed 12 patients had prostate cancer and 27 benign prostatic hypertrophy. Serum free and total PSA fell following catheterisation, while complexed PSA rose during the first 48 h then subsequently fell. The f/t PSA and c/t PSA ratios provided the best discrimination at 48 -72 h with 100% sensitivity and 75 -82% specificity. Prostate Cancer and Prostatic Diseases (2001) 4, 167-172.
Introduction
Prostate specific antigen (PSA) is recognised as the best tumour marker for prostate cancer. 1 PSA is a serine protease, which is complexed in the circulation with the protease inhibitors a 1 -antichymotrypsin and a 2 -macroglobulin. Many studies have proposed that the clinical utility of PSA can be enhanced by the determination of unbound (free) PSA and calculation of the ratios of free/total (f/t) PSA or complexed/total (c/t) PSA. 2 PSA is not a cancer specific marker and various physiological and benign pathological processes affect the serum PSA concentration. 3 Prostatitis, 4, 5 benign prostatic hypertrophy (BPH) 6 and ejaculation increase serum PSA concentration. 7 Urological procedures such as cystoscopy, transrectal ultrasound (TRUS) with or without biopsies and transurethral resection of prostate (TURP) may increase serum concentrations of PSA. 8, 9 The majority of the studies on the effect of physiological processes and investigative/interventional procedures on serum PSA have measured only total PSA. There is only limited data on the affect of such procedures on free PSA, although we have previously shown that free PSA is released following TURP. 10 BPH is associated with mild to moderate increases in serum PSA. 11 Serum PSA and prostate volume were the most powerful predictors of spontaneous acute urinary retention in placebo-treated patients in the PLESS study. 12 There have been reports suggesting that acute urinary retention may lead to a disproportionate rise in serum PSA concentration. Armitage and colleagues reported PSA concentrations greater than 10 mg/l in patients with BPH and urinary retention. 13 Markedly elevated PSA concentrations were associated with urinary retention, following cardiac surgery and extracorporeal cardiopulmonary bypass. 14 Semjonow and associates reported up to a 6-fold (mean 2.4-fold) increase in PSA concentrations in seven patients with acute urinary retention following cardiac surgery and cardiopulmonary bypass. 15 The increased serum PSA concentration in these patients decreased over the 48 h following suprapubic cystostomy and relief of their retention. There are no studies on the effect of urinary retention on the distribution of serum PSA between the free and complexed forms. There are also reports of elevated serum acid phosphatase (PAP) concentrations in acute urinary retention, which decrease following catheterisation and are associated with prostatic infarction. 16 It is suggested that in acute urinary obstruction, prostatic micro-infarction leads to release of PSA into the blood circulation, although the exact mechanism by which urinary obstruction leads to infarction is unclear. 17 The aims of this study were:
(1) To study the serum PSA kinetics in acute urinary retention and catheterisation. (2) To investigate whether PSA alone, f/t PSA ratio or c/t PSA ratios predict cancer of the prostate gland (CaP) in the retention setting and which provides the best discrimination between benign and malignant disease. (3) To determine the optimum time interval after catheterisation for measurement of PSA and the f/t PSA or c/t PSA ratios to have diagnostic value.
Materials and methods
The study comprised 39 patients from two centres, who presented with acute urinary retention to the casualty departments. Blood was taken, into tubes without anticoagulant, for free, total PSA and complexed PSA analysis before catheterisation and at 48 and 72 h post-catheterisation. Blood samples were centrifuged at 2000 g for 15 min within 1 h of collection and the serum stored at 7 20 C until assayed. Patients with overt urinary infections (dysuria and fever), haematuria and chronic retention (residual urine volume greater than 1.5 l of urine and/or deranged renal function) were excluded from the study. Digital rectal examination (DRE) was performed in all patients following blood sampling and patients who had suspicious findings on DRE (n ¼ 4) had TRUS and biopsies 7 -10 days after their acute admission (three had benign disease). The remainder of the patients were given 400 mg of Tamsulosin (Flomax, Yamanouchi Europe B.V., Meppel, The Netherlands) daily and were monitored for 72 h. All patients subsequently underwent trial without catheter (TWOC) after the 72 h blood specimen had been taken. Only one patient had a successful TWOC (he subsequently had TRUS for suspicious DRE with benign histology). All other patients subsequently underwent TURP and histological examination of the prostate tissue was carried out. All the patients who underwent TURP with benign histology had a serum PSA measured at 3 months. In the only one of these patients whose PSA was greater than 4 mg/l, sextant TRUS guided biopsies showed prostatitis.
Free and total PSA were assayed using the Delfia Prostatus dual labelled immunoassay and the free to total ratio calculated (Perkin Elmer UK, Milton Keynes). Complexed and total PSA were assayed using the Bayer Immuno 1 analyser (Bayer Diagnostics, Newbury.). The complexed PSA assay utilises a pair of antibodies to PSA to selectively measure the complexed forms of PSA. ME2 is an antibody which binds to free PSA at an epitopic site shielded when PSA is complexed to a 1 -antichymotrypsin or other protease inhibitors. When ME2 is bound to PSA a second antibody, MM1, is prevented from binding to PSA. Pre-incubation of a serum sample with ME2, therefore, prevents free PSA reacting to MM1. Following incubation of serum with MM1 an antibody to MM1 attached to a magnetic particle is added. When the solution is placed in a magnetic field the complexed PSA is retained and the free PSA is washed out of the reaction vessel. A further antibody to another epitopic site of PSA, which is attached to alkaline phosphatase, is then added. Addition of a substrate to alkaline phosphatase results in a colour change which is directly proportional to the concentration of complexed PSA. The assay measures PSA complexed to any protease inhibitor with the exception of a 2 -macroglobulin. The DELFIA f/t PSA methods produces slightly lower results than the Bayer method due to differences in the composition of the standards used. Total PSA cannot therefore be calculated on the basis of free þ complexed PSA.
Statistical analysis was carried out using the Analyse-It medical statistics add-in to Microsoft Excel. Receiver operating characteristics (ROC) curves were determined for total PSA, f/t PSA ratio and c/t PSA ratio as a means of comparing the relative efficiency of each parameter in differentiating benign and malignant prostatic disease. As the data was not normally distributed the Mann -Whitney test was used for comparisons between the benign and malignant prostate disease groups.
Results
On reviewing the histology of the 39 patients, 12 were found to have prostate cancer and the rest (27) had BPH. Four patients in the BPH group also had prostatitis. The overall mean age of the patients was 72.3 y (s.d. 7.7 y). For the BPH group the mean age was 71.7 y (7.4 y) and for the prostate cancer group 75.3 y (7.9 y). There was no statistically significant difference in the ages of the two groups (P ¼ 0.12, Mann -Whitney).
The medians and interquartile ranges (IQR) for free and total PSA and their ratio for the BPH and prostate cancer groups are shown in Table 1 . For the overall patient group the median total PSA at time 0 (before catheterisation) was 11.7 mg/l (IQR 17.8 mg/l) which fell progressively to 9.5 mg/l (13.2 mg/l) at 72 h. Similarly free PSA fell from a median of 2.44 mg/l (3.5 mg/l) before catheterisation to 1.25 mg/l (2.4 mg/l) at 72 h. Similar falls in total and free PSA were seen when the patients were divided into BPH and CaP subgroups with the lowest results at 72 h ( Table 1 ). The median f/t PSA ratios for the BPH and cancer groups at time 0 were 0.28 (0.19) and 0.15 (0.08) respectively. At 48 h the ratio in the BPH group had fallen to 0.22 (0.1) which did not significantly change over the following 24 h 0.23 (0.09). For the prostate cancer group the median ratio also fell at 48 h to 0.11 (0.07) and to 0.1 (0.05) at 72 h.
The free, total PSA and the f/t PSA ratio were compared between BPH and prostate cancer groups using the Mann -Whitney test to see whether discrimination between malignant and benign disease of the prostate could be achieved (Table 1) . At no time was free PSA able to discriminate between the two groups. Total PSA was a slightly better discriminator between the two groups at 48 h (P ¼ 0.009). At all time points the f/t PSA ratio was the best discriminator (P < 0.001).
Receiver operator characteristics (ROC) curves were also drawn for the three parameters of free PSA, total PSA and ratios (Table 2 ). Free PSA did not have any discriminatory potential between the two groups at any time interval (P > 0.05). Total PSA was significantly more useful in differentiating the two groups, but the f/t ratio provided the best discrimination at all time points.
The sensitivity, specificity, positive and negative predictive values and efficiency of the test for free PSA, total PSA and the f/t PSA ratio are shown in Table 3 . For free PSA even using a cut-off value as low as 1 mg/l the efficiency of the test did not exceed 50%, with the best result being obtained at 48 h. Total PSA measurements were evaluated with two differing values based on the data obtained from the ROC analysis. The lower value was chosen to maximise sensitivity and the higher value to maximise specificity. If a value of 4.4 mg/l is taken as the upper limit of normal for total PSA, then the 72 h sample appears to provide the best discrimination. For a value of 9.5 mg/l, however, the 48 h is marginally better. Total PSA value at time 0 using the 4.4 mg/l cut-off, has maximum sensitivity (92%) but poor specificity (26%). For the f/t PSA ratio a cut-off of 0.18 produced 100% sensitivity and 82% specificity at 72 h, giving a test efficiency of 87%. Using the f/t PSA ratio commonly quoted as providing best discrimination between benign and malignant disease in patients without retention (0.23) inferior results were achieved compared to an f/t PSA ratio of 0.18.
The medians and IQR for total and complexed PSA and their ratios are shown in Table 4 . The median complexed PSA for all the patients was 8.9 mg/l (IQR 14.5 mg/l). This increased to a median of 10.1 mg/l (13.9 mg/l) at 48 h and fell to a median value of 8.7 mg/l (13.9 mg/l) at 72 h. The median c/t PSA ratio for all patients at time 0 was 0.88 (0.15) which increased to 0.93 (0.09) at 48 h and 0.92 (0.13) at 72 h. There was a rise in complexed PSA in both the BPH and CaP groups at 48 h compared to the sample taken prior to catheterisation. Subsequently the complexed PSA fell to values less than the starting concentration. The c/t PSA ratio, however, increased in both groups over the 72 h. ROC curves ( Table 5 ), showed that complexed PSA on its own was significant in differentiating cancer patients from BPH at all the time intervals, the best time interval, being after 48 h (P ¼ 0.0008). The c/t PSA ratio was, however, a better discriminator at all time intervals (P < 0.0001). The sensitivity, specificity, positive and negative predictive values and efficiency of the test for complexed PSA and the c/t PSA ratio are shown in Table 6 . For complexed PSA the greatest test efficiency was obtained using the 72 h sample (74%) with a cut-off at 10 mg/l, where the sensitivity and the specificity were 75 and 74% respectively. For the c/t PSA ratio a sensitivity of 100% with a specificity of 75% was achieved at 48 h if a cut-off of 0.91 was used.
Discussion
It is a common belief among many urologists that PSA measurement is not useful in predicting cancer in patients with acute urinary retention. Increases in PSA and PAP concentrations following retention which have been observed in a few anecdotal reports, fall after catheterisation. 13, 15, 16 It is suggested that in acute urinary obstruction, prostatic microinfarction leads to the release of PSA into the blood circulation, although the mechanism by which urinary obstruction leads to infarction is unclear. 17 This is the first study looking at the total, free and complexed PSA kinetics in patients treated for acute urinary retention in a prospective setting. The plasma PSA concentration is a function of PSA production by prostate epithelial cells, of leakage into the circulation and of clearance. 9 The architecture of the basement membrane of the prostate gland is believed to act as a barrier between the high concentration of PSA in the ductal lumen and the blood plasma. A small fraction of PSA can diffuse through this barrier into plasma and in normal circumstances the concentration of PSA in plasma is usually < 4 mg/l. 6 This corresponds to not more than 10 76 of the normal concentration of PSA delivered into the seminal fluid. 2 Disease processes that disrupt the basement membrane, for example carcinoma, BPH, PSA measurements in men with urinary retention S Sriprasad et al inflammation (and possibly urinary retention) increase plasma PSA concentration. 10 Most of the small quantities of enzymatically active PSA that do escape into the intercellular spaces is immediately inactivated by complexing with the protease inhibitors. Two mainly liver derived protease inhibitors, a 1 -antichymotrypsin (ACT) and a 2 -macroglobulin (AMG), occur at large molar excess to PSA (100-fold) in extracellular fluids and regulate the PSA activity in blood in vitro by the formation of covalent complexes with the active, single chain form of PSA. 18 In addition to ACT there are other inhibitors belonging to the serpin super family of serine protease inhibitors which form covalent complexes with PSA, such as, a 1 -antitrypsin and the protein C inhibitor. 19 As seen in our study the median total and free PSA falls after catheterisation, but there is an initial rise in complexed PSA over the first 48 h, presumably due to binding to protease inhibitors of active PSA. There is no convincing explanation for the pathophysiology of the rise in PSA in retention. Spiro and associates demonstrated that 85% of the prostates removed (by suprapubic prostatectomy) from patients with acute urinary retention showed evidence of recent prostatic infarction. 17 Hicks reported a case in which a 74-y-old man presenting with acute urinary retention had a PSA of 232 mg/l with no evidence of prostatitis and negative TRUS guided sextant biopsies. The patient subsequently underwent a TURP and the histology showed multiple areas of healing infarctions and small pockets of liquefaction. 20 Similar findings were reported by Collier et al in patients with raised serum acid phosphatase with urinary retention where two of the seven patients had prostatic infarction. 16 However, most urologists will agree that we seldom see a histological report of prostatic infarction in prostate specimens from patients who undergo TURP for urinary retention. BPH is associated with mild to moderate increases in serum PSA. 6 This is generally attributed to increased prostate size, and a direct correlation has been reported between the weight of the resected prostate at TURP for prostatism and the pre-operative serum PSA concentration. 13 The PLESS study suggests that the serum PSA concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical BPH. 12 One should not forget that patients with prostate cancer can have a significant amount of coexisting BPH. There is a paucity of information in the literature as to why PSA rises in retention. It is plausible that although seldom documented, prostatic infarction does occur and this inflammatory/ischaemic process makes the prostatic basement membrane more permeable, thereby increasing the leakage of PSA into plasma. Alternatively, the distended bladder may result in compression of the prostate gland causing PSA to leak across the basement membrane into the circulation. This would be particularly relevant in subjects with large benign hyperplastic prostates.
This study clearly indicates that whilst a total PSA measured in samples taken 48 h after catheterisation was higher in prostate cancer patients compared to BPH (P ¼ 0.009), total PSA is not discriminatory pre-catheterisation (P ¼ 0.06). Free PSA on its own is not a significant discriminator at any time point. The f/t PSA ratio provides the best discrimination at any time interval (P < 0.0001). A cut-off f/t PSA ratio of 0.18 at 72 h gives 100% sensitivity and satisfactory specificity (82%). Complexed PSA alone can differentiate between BPH and CaP at all time intervals, but the optimum time of sampling is again at 48 h (P ¼ 0.0008). The c/t PSA ratio is discriminatory at all time intervals (P < 0.0001). The best results for c/t PSA ratio are obtained for a cut-off value of 0.91 at 48 h where sensitivity is 100% and specificity is 75%. The f/t PSA ratio is therefore marginally better than the c/t ratio but the difference is slight.
Prostate cancer was excluded by a combination of TURP biopsy and post-operative normalisation of the PSA, or transrectal biopsy where there was a persistently elevated PSA post-operatively. We accept that there may be a risk of missing some very early prostate cancers but would regard these in most clinicians' eyes as being 'insignificant' tumours. Despite the clear statistical power shown earlier, the study size was small and would benefit from being repeated in a larger and multi-centre replication trial. Such a trial could be conducted prospectively using the data obtained from this study.
In conclusion, PSA measurement in retention is useful if either the f/t or c/t PSA ratio are determined according to local availability. The sample should be taken at least 48 h after catheterisation to ensure reliable results. The f/t and c/t PSA ratio can be easily determined. It would be prudent to determine these ratios in young and fit patients who have no co-morbidity, in whom one would consider definitive treatment if they have been found to have prostate cancer and present with acute urinary retention. If they have a f/t PSA ratio of less than 0.18 or c/t PSA ratio greater than 0.91 then they should have TRUS and sextant biopsies before TURP is considered. Why not carry out a TURP and treat any subsequent prostate cancer separately? Apart from the unnecessary surgery and cost involved, we find that prior TURP may make subsequent radical prostatectomy more difficult due to scarring at the bladder neck or distortion of the ureteric orifices. In addition, we have shown shedding of malignant cells into the circulation during TURP 21 for cancerous prostates, although the clinical significance is unknown as yet.
